Zecotek Announces Non-Brokered Private Placement

SINGAPORE—(Marketwired – December 29, 2017) –

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I), a developer of leading–edge photonics technologies for medical, industrial and scientific markets, today announced that the Company has arranged for a non–brokered private placement of 10,000,000 units of the Company at a price of $0.30 per unit for gross proceeds of $3,000,000.

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of $0.43 per common share at any time on or before the 24–month anniversary of the closing of the offering.

Net proceeds from the funds raised will be used to complete the transfer of technology for the purpose of immediate commercialization, strengthen and maintain patents of the Company's IP portfolio, and used for purchase order financings and general working capital purposes. Pursuant to the financing, the Company may pay a finder's fee.

All shares and warrants are subject to a four–month hold period.

About Zecotek
Zecotek Photonics Inc (TSX VENTURE: ZMS) (FRANKFURT: W1I) is a photonics technology company developing high–performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto–stereoscopic displays, 3D metal printing, and lasers for applications in medical, high–tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners including Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Opto–Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com, follow @zecotek on Twitter.

This press release may contain forward–looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

SiTune to Host Suite at CES 2018

SAN JOSE, CA—(Marketwired – December 29, 2017) – SiTune Corporation, an innovative pioneer in semiconductor tuners, transceivers, and wireless radios today announced it will be attending the Consumer Electronics Show (CES) in Las Vegas, NV January 9th – 12th.

SiTune will host demonstrations and discussions in a private suite at the Westgate Hotel located near the Las Vegas Convention Center.

This year's presence will focus on SiTune's range of industry leading products including the company's pioneering DOCSIS 3.1/3.0 Total Spectrum Reception (TSR™) Transceiver, its 4–Channel Terrestrial Total Spectrum Reception (TSR™) Tuner for OTT+OTA applications, and the industry's first 8K/4K 1T/1S Concurrent Tuner.

In–suite product demonstrations feature three noteworthy SiTune tuners, each offering leading–edge and best–in–class solutions to customers:

  • STN93321: The DOCSIS Cable Front–End demonstration highlights full performance DOCSIS 3.1/3.0 downstream reception and upstream transmission along with CMTS registration.
  • STN91401: SiTune's Terrestrial Tuner demonstration displays Total Spectrum Reception (TSR™) full–band terrestrial reception. With the full–band reception comes fast channel change and for the first time, spectrum monitoring capability for broadcast operators.
  • STN6528: Demonstration of the industry's first 1T/1S Concurrent Tuner features best–in–class ISDB–S3 video signal reception.

“SiTune always looks forward to meeting our customers at CES” said Ben Runyan, SiTune's VP of Sales and Marketing. “This year we're particularly excited to showcase best–in–class performance offered with every tuner SiTune produces. The remarkable performance displayed in these product demonstrations signifies SiTune's continuous support to our customers helping them meet and exceed design requirements, get to market faster, and quickly adapt to evolving industry standards.”

To request a meeting or product demonstration at CES 2018, please contact SiTune at sales@situne–ic.com or contact your local sales representative.

For additional information on SiTune products please visit http://www.situne–ic.com/products. For ongoing SiTune news visit our website, or visit us on LinkedIn, Facebook, or Twitter.

About SiTune Corporation

SiTune Corporation is an innovator in radio frequency and mixed signal semiconductor solutions for wired and wireless communications. SiTune products enable voice, video, data and IoT gateways in the home and office. SiTune is headquartered in San Jose, California. For more information, please visit www.situne–ic.com.

Brixton Metals Closes Second Tranche of Private Placement for Aggregate Proceeds of $3 Million for Drilling its Cobalt Projects

VANCOUVER, BC—(Marketwired – December 29, 2017) – Brixton Metals Corporation (TSX VENTURE: BBB) (the “Company” or “Brixton“) is pleased to announce that it has closed the second tranche of its private placement of flow–through shares for gross proceeds of $1,420,750 (the “Private Placement“). The Private Placement consisted of the issuance of 5,692,000 flow–through shares (“FT Shares“) at a price of $0.25 per FT Share. Certain finders (the “Finders“) were paid commissions comprised of a cash fee in the aggregate amount of $99,610 and were issued an aggregate of 398,440 finder's warrants in connection with the Private Placement.

Each Finder's warrant is exercisable to acquire one common share of the Company at a price of $0.25 for a period of 24 months from closing of the Private Placement.

The Company intends to use the gross proceeds from the first tranche (which closed on December 7, 2017) and this closing in the aggregate amount of $3 million to advance the Company's wholly–owned Cobalt properties in the Cobalt Camp of Ontario, Canada and its other Canadian properties.

The FT Shares will be “flow–through” shares pursuant to the Income Tax Act (Canada). All securities issued under the Private Placement, including the securities issuable on exercise thereof, are subject to a hold period expiring four months and one day from the closing date.

About Brixton Metals Corporation

Brixton Metals Corporation is a gold–silver exploration & developing company with assets in Canada and USA. Brixton wholly owns 4 projects. The advanced stage Hog Heaven silver–gold–copper project in NW Montana, USA is a past producer of direct ship ore. Two district scale gold projects, “Thorn” at the northern extent of the Golden Triangle and “Atlin” gold camp in British Columbia, Canada. Lastly, two past producing high–grade silver–cobalt mines, the Langis and Hudson Bay brownfield projects with excellent infrastructure located in Ontario, Canada.

Brixton Metals Corporation shares trade on the TSX–V under the ticker symbol BBB. For more information about Brixton please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR RELEASE TO U.S. NEWSWIRE SERVICES

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward–looking statements under applicable securities laws. Forward–looking statements are statements that relate to future, not past, events. In this context, forward–looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that the use of proceeds, address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, the proposed use of proceeds from the Private Placement are forward looking statements. By their nature, forward–looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward–looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward–looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward–looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward–looking statements.

Brixton Metals Closes Second Tranche of Private Placement for Aggregate Proceeds of $3 Million for Drilling its Cobalt Projects

VANCOUVER, BC—(Marketwired – December 29, 2017) – Brixton Metals Corporation (TSX VENTURE: BBB) (the “Company” or “Brixton“) is pleased to announce that it has closed the second tranche of its private placement of flow–through shares for gross proceeds of $1,420,750 (the “Private Placement“). The Private Placement consisted of the issuance of 5,692,000 flow–through shares (“FT Shares“) at a price of $0.25 per FT Share. Certain finders (the “Finders“) were paid commissions comprised of a cash fee in the aggregate amount of $99,610 and were issued an aggregate of 398,440finder's warrants in connection with the Private Placement. Each Finder's warrant is exercisable to acquire one common share of the Company at a price of $0.25 for a period of 24 months from closing of the Private Placement.

The Company intends to use the gross proceeds from the first tranche (which closed on December 7, 2017) and this closing in the aggregate amount of $3 million to advance the Company's wholly–owned Cobalt properties in the Cobalt Camp of Ontario, Canada and its other Canadian properties.

The FT Shares will be “flow–through” shares pursuant to the Income Tax Act (Canada). All securities issued under the Private Placement, including the securities issuable on exercise thereof, are subject to a hold period expiring four months and one day from the closing date.

About Brixton Metals Corporation

Brixton Metals Corporation is a gold–silver exploration & developing company with assets in Canada and USA. Brixton wholly owns 4 projects. The advanced stage Hog Heaven silver–gold–copper project in NW Montana, USA is a past producer of direct ship ore. Two district scale gold projects, “Thorn” at the northern extent of the Golden Triangle and “Atlin” gold camp in British Columbia, Canada. Lastly, two past producing high–grade silver–cobalt mines, the Langis and Hudson Bay brownfield projects with excellent infrastructure located in Ontario, Canada.

Brixton Metals Corporation shares trade on the TSX–V under the ticker symbol BBB. For more information about Brixton please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR RELEASE TO U.S. NEWSWIRE SERVICES

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward–looking statements under applicable securities laws. Forward–looking statements are statements that relate to future, not past, events. In this context, forward–looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that the use of proceeds, address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, the proposed use of proceeds from the Private Placement are forward looking statements. By their nature, forward–looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward–looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward–looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward–looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward–looking statements.

Tecogen's Co-CEO to Retire as an Officer and Board Member, Will Continue in an Emeritus and Advisory Role

WALTHAM, MA—(Marketwired – December 29, 2017) – December 29, 2017– Tecogen® Inc. (NASDAQ: TGEN), a clean energy company providing ultra–efficient, clean, natural gas powered on–site power, heating and cooling equipment, is announcing that John Hatsopoulos, the company's Co–CEO and co–founder, has decided to retire as an officer and not run for re–election to the Board of Directors of Tecogen Inc. at the 2018 annual meeting. He will remain a Director of American DG Energy (ADGE) and Ultera Technologies, Inc. He will also continue to be actively involved with the company as an advisor to the board and Co–CEO Benjamin Locke and as an employee responsible for investor relations. Upon his retirement, Mr. Hatsopoulos will assume the title of Chairman Emeritus.

About Tecogen
Tecogen® Inc. designs, manufactures, sells, installs, and maintains high efficiency, ultra–clean, cogeneration products including natural gas engine–driven combined heat and power, air conditioning systems, and high–efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer's carbon footprint.

In business for over 30 years, Tecogen has shipped more than 2,500 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com or contact us for a free Site Assessment.

Tecogen, InVerde, Ilios, Tecochill, Ultera, and e+, are registered trademarks or trademark pending registration of Tecogen Inc.

Forward Looking Statements
This press release and any accompanying documents, contains “forward–looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward–looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward–looking statements include, among others, statements we make regarding:

  • The future structure and funding of Tecogen and any of its joint ventures.
  • The status of any intellectual property rights or assets.
  • Expected operating results, such as revenue growth and backlog.
  • Strategy for growth, product development, and market position. AND
  • Strategy for risk management.\

Forward–looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward–looking statements. Therefore, you should not rely on any of these forward–looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward–looking statements include, among others, the following:

  • Competing technological developments.
  • Lack of market interest in our joint venture's products.
  • Issues obtaining intellectual property protection.
  • Issues in the research and development of new products.
  • Tecogen's inability to properly fund its joint ventures. AND
  • Such other factors as discussed throughout the “Risk Factors” section of Tecogen's 10–K that was filed with the SEC on March 31, 2017 and can be found at www.sec.gov.

Any forward–looking statement made by us in in this press release and any accompanying documents is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward–looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Sirona Biochem Announces SGLT2 IND Submission Milestone

VANCOUVER, BC—(Marketwired – December 29, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced today that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor. The application will be reviewed by the CFDA for acceptance into clinical trials. Wanbang has confirmed it is processing a $500,000 USD payment to Sirona Biochem.

Sirona Biochem's SGLT2 inhibitor was licensed to Wanbang's subsidiary Shanghai Fosun Pharmaceuticals in 2014 with rights for China. This compound, created for the treatment of Type 2 diabetes, will be only the second SGLT2 inhibitor listed in China following the listing of AstraZeneca's earlier this year.

Since the initial licensing agreement, Fosun Pharma has invested RMB 29 million for the research and development of the SGLT2 inhibitor. With acceptance of the IND application by the CFDA, Fosun Pharma will begin clinical trials, triggering another milestone payment to Sirona Biochem.

“We are very pleased with the progress that has been made by Wanbang thus far with the SGLT2 inhibitor and are eager to see the project through to clinical trials. With clinical trials also planned for our skin lightening agent TFC–1067 in 2018, this demonstrates the enormous potential of our proprietary platform technology,” said Dr. Howard Verrico, CEO.

About Jiangsu Wanbang Biopharmaceuticals

A leading pharmaceutical company in China, Jiangsu Wanbang Pharmaceuticals manufactures and sells a variety of products including those for chronic disease treatment, antibiotics, and other endocrine diseases. Their subsidiary Fosun Pharma is driven by drug research and innovation, continuously investing in and optimizing their drug development capabilities.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward–looking statements. Forward–looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward–looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward–looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward–looking statements except as required by law.